JPX · 4519.T
Chugai Pharmaceutical Co., Ltd.
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
Loading market information…
JPX · 4552.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
JCR Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.98% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
JCR Pharmaceuticals Co., Ltd.’s forward annual dividend is ¥20 per share, paid semi-annual. The forward yield is 3.68% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
JCR Pharmaceuticals Co., Ltd.’s next earnings report is currently expected on Jan 28, 2027, with estimated earnings per share of -¥14. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow JCR Pharmaceuticals Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:28 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2026 | Jul 30, 2025 | -¥4-202.75% vs estimate | ¥8.57B-11.45% vs estimate |
|---|
| Q4 2025 | May 13, 2025 | -¥34+37.06% vs estimate | ¥7.19B+0.63% vs estimate |
|---|
| Q3 2025 | Jan 31, 2025 | ¥1-90.52% vs estimate | ¥9.22B-10.71% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
¥2,571+¥58 (+2.31%)
Astellas Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.37% below the high.
¥2,256+¥32 (+1.42%)
Ono Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.65% below the high.
¥1,440+¥19 (+1.34%)
Nxera Pharma Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
¥917-¥27 (-2.86%)
SanBio Company Limited’s quoted price sits in the lower half of its reported 52-week range, 68.74% below the high.
¥273-¥5 (-1.8%)
Healios K.K.’s quoted price sits in the lower half of its reported 52-week range, 45.29% below the high.
¥29+¥1 (+3.57%)
AnGes, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.82% below the high.
¥403-¥16 (-3.82%)
J-Pharma Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.19% below the high.
